TMX Newsfile·2026-01-14 21:37Core Viewpoint - A securities fraud lawsuit has been filed against Agilon Health, Inc. (NYSE: AGL) following a significant drop in its stock price after the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Agilon Health's shares fell over 25% in after-hours trading on August 4, 2025, due to the unexpected resignation of CEO Steven Sell and the withdrawal of the company's full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Legal Allegations - The lawsuit alleges that Agilon Health recklessly issued guidance for 2025 that was unlikely to be achieved, given known industry challenges [3]. - It is claimed that Agilon materially overstated the financial benefits from strategic actions intended to mitigate risks, leading to misleading statements about its business and prospects [3]. Group 3: Investor Information - Investors who purchased Agilon Health common stock between February 26, 2025, and August 4, 2025, may be eligible to recover losses, regardless of whether they sold their shares [4]. - The deadline to seek appointment as lead plaintiff in the lawsuit is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about Agilon Health are encouraged to assist in the investigation or report to the SEC under the whistleblower program, with potential rewards of up to 30% of any successful recovery [6]. Group 5: Legal Firm Background - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].